EICHORPublic-registry trials using IBI3027 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
IBI3027 appears in 1 registered trial Eichor's radar has found, sponsored by Innovent Biologics (Suzhou) Co. Ltd., the most recent registered as Phase 3, with a planned enrollment of 520. Registered timeline: 2026–2028. The registry holds 1,761 registered studies for Atopic Dermatitis.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Atopic Dermatitis | PHASE3 | 1 |
| Status | Not Yet Recruiting · planned start 2026-10 |
| Primary completion | 2028-07 |
| Enrollment target | 520 participants |
| Design | Randomized · Parallel · Phase 3 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 1 listed in China |
All fields verbatim from the ClinicalTrials.gov record for NCT07754786.
| First registered study | March 2026 — NCT07502534 (Innovent Biologics (Suzhou) Co. Ltd.) |
| Registered studies matching this name | 2 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 1,761 registered studies for Atopic Dermatitis. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Atopic Dermatitis drugs
← Eichor home · All tracked trials · Atopic Dermatitis studies · Weekly briefs
